Ventricular Septal Defects Treatment & Management

  • Author: Prema Ramaswamy, MD; Chief Editor: Stuart Berger, MD   more...
 
Updated: Nov 1, 2011
 

Approach Considerations

Children with small ventricular septal defects (VSDs) are asymptomatic and have an excellent long-term prognosis. Neither medical therapy nor surgical therapy is indicated. Prophylactic antibiotic prophylaxis against endocarditis is no longer indicated. For more information, see Antibiotic Prophylactic Regimens for Endocarditis. Maintenance of good oral hygiene is of paramount importance in reducing the risk of endocarditis.

In children with moderate or large VSDs, a trial of medical therapy is indicated to manage symptomatic congestive heart failure (CHF) because many VSDs may become smaller with time.

Uncontrolled CHF with growth failure and recurrent respiratory infection is an indication for surgical repair. Neither the age nor the size of the patient is prohibitive in considering surgery.

Large, asymptomatic defects associated with elevated pulmonary artery (PA) pressure are often repaired when infants are younger than 1 year, typically around age 6 years. Surgical repair is indicated in older asymptomatic children with a normal pulmonary pressure if the pulmonary-to-systemic flow ratio (Qp:Qs) is greater than 2:1.

Prolapse of an aortic valve cusp is an indication for surgery even if the VSD is small. Early repair may prevent progression of the aortic insufficiency.

Elevated pulmonary resistance may be maintained in some patients despite therapy directed at the VSD and may, in fact, represent a primary disease of the pulmonary vessels.

Next

Medical Management of Symptomatic CHF

Therapies used to manage symptomatic CHF in children with moderate or large VSDs may include the following:

  • Increased caloric density of feedings to ensure adequate weight gain - Occasionally, oral feeds must be supplemented with tube feeds because a baby in CHF may be unable to consume adequate calories for appropriate weight gain
  • Diuretics (eg, furosemide) to relieve pulmonary congestion - Furosemide is usually given in a dosage of 1-3 mg/kg/d divided in 2 or 3 doses; long-term furosemide treatment results in hypercalcemia and renal damage and electrolyte disturbances
  • Angiotensin-converting enzyme (ACE) inhibitors (eg, captopril and enalapril) - These medications reduce both the systemic and pulmonary pressures (the latter to a greater degree), thereby reducing the left-to-right shunt
  • Digoxin (5-10 µg/kg/d) - This may be indicated if diuresis and afterload reduction do not relieve adequately symptoms
Previous
Next

Intracardiac Repair of Defect

The first operation described for the treatment of a VSD was a palliative one and involved placing a restrictive band across the main PA.[13] This approach was proposed because pulmonary vascular disease as a result of unimpeded flow to the lungs was recognized as a dreaded complication of a VSD. The procedure was popular for about 2 decades because it was associated with low mortality and morbidity.

The first intracardiac repair of a VSD was performed in 1954 by Lillehei et al, who used a parent as an oxygenator and a pump in controlled cross-circulation.[14] The current techniques of hypothermia and cardiopulmonary bypass were first reported in the 1970s.[15, 16, 17]

Surgical closure

At present, direct surgical repair using cardiopulmonary bypass is the preferred surgical therapy in most centers. PA banding, part of a 2-stage procedure, is largely reserved for critically ill infants with multiple VSDs or for those with associated anomalies.

Most perimembranous and inlet VSDs are repaired via a transatrial surgical approach. Defects in the outlet septum are approached through the pulmonary valve. Multiple muscular defects, especially near the apex, pose a difficult problem. Initial pulmonary banding or left ventricular (LV) approach through an apical left ventriculotomy and closing the defect with a single patch are the standard techniques.

Short-term results of video-assisted cardioscopy for intraventricular repair of VSD have led to its wide adoption as a means of reducing surgical trauma. Short-term results are excellent.

Transcatheter therapy (see below) remains an experimental approach. A hybrid operation is a joint procedure involving the interventional cardiologist and the cardiac surgeon, who concomitantly optimize surgical management of complex congenital heart disease. This approach may be used for multiple VSDs where the perimembranous VSD is repaired surgically and the muscular VSDs are closed with a transcatheter device.

Transcatheter closure

Muscular VSDs have been closed with transcatheter devices for the past 15 years. Perimembranous VSDs, though relatively common, can be difficult to close percutaneously. With previous devices (eg, Rashkind or button devices), attempts to close the VSDs have been unsuccessful, because of the proximity of the defects to the aortic valve and potential aortic valve damage.

The Amplatzer membranous VSD occluder (AGA Medical Corporation; Golden Valley, Minnesota), has undergone phase I trials in the United States. This device is an asymmetric, self-expandable, double-disk unit. Current recommendations are to use this device in older patients who weigh more than 8 kg and who have a subaortic rim of more than 2 mm.

Most procedures are performed with the patient under general anesthesia and with echocardiographic guidance. Reported complications have included aortic and tricuspid regurgitation, device embolization, complete heart block, transient left bundle-branch block (LBBB), hemolysis, small residual shunts, and perforation.

In a phase I study, Fu et al reported 3 adverse events of complete heart block, perihepatic bleeding, and rupture of tricuspid valve chordae tendineae.[18] In a previous article, they reported 2 cases of transient heart block that responded to high-dose steroids.[19] Subsequent studies found that the Amplatzer membranous VSD occluder resulted in excellent closure rates but had an unacceptably high rate of complete heart block.[20, 21]

Complications

A murmur of a residual VSD is not infrequent. Selective use of intraoperative transesophageal echocardiography (TEE) to assess closure may be useful. Decisions regarding reoperation are based on symptoms, left heart size, pulmonary pressure, and degree of shunting.

Right bundle branch block (RBBB) is common and may be caused by ventriculotomy or direct injury to the right bundle itself. Complete heart block can rarely occur and is associated with late mortality. LV dysfunction may occur after left ventriculotomy to close a muscular VSD. Ventricular arrhythmia can be a late problem.

Previous
Next

Special Concerns in Pregnant Women

Pregnancy and prenatal care

The presence or lack of early care is not a factor in congenital cardiovascular malformations (CCVMs).

VSD associated with pulmonary vascular disease is one of the 2 major maternal cardiac risks; the other is pulmonary edema. A major objective of medical management is to minimize the factors that interfere with the limited circulatory reserve of pregnant women with VSDs. Diuretics can be used judiciously to manage edema of cardiac failure, but they should not be used to treat edema of normal pregnancy.

Pregnant women with heart disease should limit themselves to moderate isotonic exercise. Maternal mortality in pregnant women with heart disease has been associated with the functional class.

Because anxiety is a special concern in a primigravida, the expectant mother should be prepared mentally for pregnancy, labor, delivery, and puerperium.

Labor and delivery

In women with functionally mild unoperated lesions and in patients after successful surgical repair, management of labor and delivery is the same as for pregnant women without a VSD.

The recommendations of the American Heart Association state that no antibiotic prophylaxis is required for a normal vaginal delivery.

For pregnant women with functionally important congenital cardiac disease (unoperated or operated), the management of labor, delivery, and the puerperium is crucial to minimize risk.

Induced vaginal delivery is preferred over cesarean delivery. Cesarean delivery results in twice the blood loss of vaginal delivery. In addition, it is associated with risks of wound infection, uterine infection, thrombophlebitis, and potential postoperative complications.

Previous
Next

Activity Restriction

Lifestyle changes (ie, exercise before and after surgery or catheterization) may not be required.

A restrictive VSD with a functional normal heart imposes no exercise limitation. Although patients can safely participate in competitive sports without restriction, adults in this category are uncommon. An important exception is the adult whose moderately restrictive perimembranous VSD decreased in size or closed spontaneously in infancy. However, 2-dimensional (2D) echocardiography with Doppler interrogation and color flow imaging should be performed to determine whether the defect closed by means of formation of a septal aneurysm.

Unrestricted exercise after surgical closure of a moderate-to-large VSD is permitted if the following criteria are met:

  • Acceptable postoperative PA pressure
  • Absence of clinically significant disturbances in ventricular rhythm during maximal exercise stress testing and during 24-hour ambulatory electrocardiography
  • 2D echocardiographic evidence of an intact ventricular septum with normalization of LV and left atrial (LA) size and LV function
  • 12-lead scalar electrocardiogram (ECG) revealing little or no evidence of LV volume overload or right ventricular (RV) pressure overload
Previous
Next

Long-Term Monitoring

After intracardiac repair of a VSD, long-term follow-up is necessary. Even patients with small VSDs require indefinite follow-up.

Patients with perimembranous VSDs who have undergone aneurysmal closure have a high incidence of LV-to-right atrium (RA) shunting and a 6% incidence of subaortic ridge, as shown in a large Chinese study.[6]

With increasing age, the incidence of aortic leaflet prolapse and aortic insufficiency increases in children with the doubly committed and perimembranous type of VSD.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Prema Ramaswamy, MD  Associate Professor of Clinical Pediatrics, State University of New York Downstate; Adjunct Assistant Clinical Professor of Pediatrics, St George's University School of Medicine; Co-Director of Pediatric Cardiology, Maimonides Medical Center, Lutheran Medical Center, and Coney Island Hospital

Prema Ramaswamy, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Cardiology

Disclosure: Nothing to disclose.

Coauthor(s)

Kuruchi Srinivasan, MD  Consulting Staff, Department of Internal Medicine, Nazareth Hospital

Kuruchi Srinivasan, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Stuart Berger, MD  Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin

Stuart Berger, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American College of Chest Physicians, American Heart Association, and Society for Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Additional Contributors

Patturajah Anbumani, MD, MBBS, MS, MCh Associate Medical Director, Best Medical Care; Former Associate Medical Director, Jeanes Hospital, Temple University Health System; Former Adjunct Clinical Assistant Professor, New York College of Osteopathic Medicine; Former Clinical Assistant Professor, Department of Medicine, State University of New York-Downstate

Patturajah Anbumani, MD, MBBS, MS, MCh is a member of the following medical societies: American College of Physicians, American Medical Association, and American Medical Women's Association

Disclosure: Nothing to disclose.

Hugh D Allen, MD Professor, Department of Pediatrics, Division of Pediatric Cardiology and Department of Internal Medicine, Ohio State University College of Medicine

Hugh D Allen, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Pediatric Society, American Society of Echocardiography, Society for Pediatric Research, Society of Pediatric Echocardiography, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Viswanath Natesan, MD Staff Physician, Department of Internal Medicine, Lutheran Medical Center

Disclosure: Nothing to disclose.

Ashmitha Srinivasan Drexel University College of Medicine

Disclosure: Nothing to disclose.

Sharmila Srinivasan State University of New York Upstate Medical University

Disclosure: Nothing to disclose.

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA Professor, Departments of Pediatrics (Cardiology), Cardiovascular Sciences, and Molecular and Human Genetics, Baylor College of Medicine; Chief of Pediatric Cardiology, Foundation Chair in Pediatric Cardiac Research, Texas Children's Hospital

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Cardiology, American College of Sports Medicine, American Heart Association, American Medical Association, American Society of Human Genetics, Cardiac Electrophysiology Society, New York Academy of Sciences, Society for Pediatric Research,Texas Medical Association, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Additional Contributors

Patturajah Anbumani, MD, MBBS, MS, MCh Associate Medical Director, Best Medical Care; Former Associate Medical Director, Jeanes Hospital, Temple University Health System; Former Adjunct Clinical Assistant Professor, New York College of Osteopathic Medicine; Former Clinical Assistant Professor, Department of Medicine, State University of New York-Downstate

Patturajah Anbumani, MD, MBBS, MS, MCh is a member of the following medical societies: American College of Physicians, American Medical Association, and American Medical Women's Association

Disclosure: Nothing to disclose.

Hugh D Allen, MD Professor, Department of Pediatrics, Division of Pediatric Cardiology and Department of Internal Medicine, Ohio State University College of Medicine

Hugh D Allen, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Pediatric Society, American Society of Echocardiography, Society for Pediatric Research, Society of Pediatric Echocardiography, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Viswanath Natesan, MD Staff Physician, Department of Internal Medicine, Lutheran Medical Center

Disclosure: Nothing to disclose.

Ashmitha Srinivasan Drexel University College of Medicine

Disclosure: Nothing to disclose.

Sharmila Srinivasan State University of New York Upstate Medical University

Disclosure: Nothing to disclose.

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA Professor, Departments of Pediatrics (Cardiology), Cardiovascular Sciences, and Molecular and Human Genetics, Baylor College of Medicine; Chief of Pediatric Cardiology, Foundation Chair in Pediatric Cardiac Research, Texas Children's Hospital

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Cardiology, American College of Sports Medicine, American Heart Association, American Medical Association, American Society of Human Genetics, Cardiac Electrophysiology Society, New York Academy of Sciences, Society for Pediatric Research,Texas Medical Association, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Roger H. Clinical researches on the congenital communication of the two sides of the heart by failure of occlusion of the interventricular septum. Bull de l' Acad de Med. 1879;8:1074.

  2. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. Sep 27 1958;755-62. [Medline].

  3. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. Oct 1958;18(4 Part 1):533-47. [Medline].

  4. Van Praagh R, Geva T, Kreutzer J. Ventricular septal defects: how shall we describe, name and classify them?. J Am Coll Cardiol. Nov 1 1989;14(5):1298-9. [Medline].

  5. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation. Feb 1993;87(2 Suppl):I38-51. [Medline].

  6. Wu MH, Wu JM, Chang CI, et al. Implication of aneurysmal transformation in isolated perimembranous ventricular septal defect. Am J Cardiol. Sep 1 1993;72(7):596-601. [Medline].

  7. Wu MH, Wang JK, Lin MT, et al. Ventricular septal defect with secondary left ventricular-to-right atrial shunt is associated with a higher risk for infective endocarditis and a lower late chance of closure. Pediatrics. Feb 2006;117(2):e262-7. [Medline].

  8. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol. Jun 1993;46(6):581-9. [Medline].

  9. Roguin N, Du ZD, Barak M, Nasser N, Hershkowitz S, Milgram E. High prevalence of muscular ventricular septal defect in neonates. J Am Coll Cardiol. Nov 15 1995;26(6):1545-8. [Medline].

  10. Corone P, Doyon F, Gaudeau S, et al. Natural history of ventricular septal defect. A study involving 790 cases. Circulation. Jun 1977;55(6):908-15. [Medline].

  11. Pongiglione G, Freedom RM, Cook D, Rowe RD. Mechanism of acquired right ventricular outflow tract obstruction in patients with ventricular septal defect: an angiocardiographic study. Am J Cardiol. Oct 1982;50(4):776-80. [Medline].

  12. Zielinsky P, Rossi M, Haertel JC, et al. Subaortic fibrous ridge and ventricular septal defect: role of septal malalignment. Circulation. Jun 1987;75(6):1124-9. [Medline].

  13. Muller WH, Danimann JF. The treatment of certain congenital malformations of the heart by the creation of pulmonic stenosis to reduce pulmonary hypertension and excessive pulmonary blood flow; a preliminary report. Surg Gynecol Obstet. Aug 1952;95(2):213-9. [Medline].

  14. Lillehei CW, Cohen M, Warden HE. The results of direct vision closure of ventricular septal defects in eight patients by means of controlled cross circulation. Surg Gynecol Obstet. Oct 1955;101(4):446-66. [Medline].

  15. Barratt-Boyes BG, Neutze JM, Clarkson PM, et al. Repair of ventricular septal defect in the first two years of life using profound hypothermia-circulatory arrest techniques. Ann Surg. Sep 1976;184(3):376-90. [Medline].

  16. Barratt-Boyes BG, Simpson M, Neutze JM, et al. Intracardiac surgery in neonates and infants using deep hypothermia with surface cooling and limited cardiopulmonary bypass. Circulation. May 1971;43(5 Suppl):I25-30. [Medline].

  17. Castaneda AR, Lamberti J, Sade RM, et al. Open-heart surgery during the first three months of life. J Thorac Cardiovasc Surg. Nov 1974;68(5):719-31. [Medline].

  18. Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial. J Am Coll Cardiol. Jan 17 2006;47(2):319-25. [Medline].

  19. Yip WC, Zimmerman F, Hijazi ZM. Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect. Catheter Cardiovasc Interv. Nov 2005;66(3):436-41. [Medline].

  20. Predescu D, Chaturvedi RR, Friedberg MK, Benson LN, Ozawa A, Lee KJ. Complete heart block associated with device closure of perimembranous ventricular septal defects. J Thorac Cardiovasc Surg. Nov 2008;136(5):1223-8. [Medline].

  21. Szkutnik M, Kusa J, Bialkowski J. Percutaneous closure of perimembranous ventricular septal defects with Amplatzer occluders--a single centre experience. Kardiol Pol. Sep 2008;66(9):941-7; discussion 948-9. [Medline].

Previous
Next
 
A: Image shows a ventricular septum viewed from the right side. It has the following 4 components: inlet septum from the tricuspid annulus to the attachments of the tricuspid valve (I); trabecular septum from inlet to apex and up to the smooth-walled outlet (T); outlet septum, which extends to the pulmonary valve (O); and membranous septum. B: Anatomic positions of the defects are as follows: outlet defect (a); papillary muscle of the conus (b); perimembranous defect (c); marginal muscular defects (d); central muscular defects (e); inlet defect (f); and apical muscular defects (g).
Schematic representation of the location of various types of ventricular septal defects (VSDs) from the right ventricular aspect. A = Doubly committed subarterial ventricular septal defect; B = Perimembranous ventricular septal defect; C = Inlet or atrioventricular canal–type ventricular septal defect; D = Muscular ventricular septal defect.
Supracristal ventricular septal defect (VSD). Top image: Parasternal long-axis view shows the defect just below the aortic root. Middle image: The plane of sound is tilted to view the right ventricular outflow tract, and the defect is observed below the pulmonic valve. Bottom image: Parasternal short-axis view shows the ventricular septal defect between the aortic root (Ao) and the pulmonic valve (PV). LA = Left atrium; LV = Left ventricle; PA = Pulmonary artery; RA = Right atrium; RV = Right ventricle.
Echocardiogram of a child with a perimembranous ventricular septal defect (VSD). Note the defect at the 10 o'clock position in the parasternal short-axis view. AO = Aortic root; LA = Left atrium; LV = Left ventricle; PA = Pulmonary artery; RA = Right atrium; RV = Right ventricle.
Apical 4-chamber views. A: Image shows a large inlet defect. The defect is posterior and at the level of the atrioventricular valves. B: Image shows a small midmuscular ventricular septal defect. LA = Left atrium; LV = Left ventricle; PA = Pulmonary artery; RA = Right atrium; RV = Right ventricle.
Table. Aneuploid Syndromes Associated with Ventricular Septal Defect
SyndromeCCVM (%)Type of CCVM
Del 4q, 21, 3260Ventricular septal defect, atrial septal defect
Del 5p30-60Ventricular septal defect
Trisomy 1380Atrial septal defect, ventricular septal defect, TOF
Trisomy 18, Edwards syndrome100Ventricular septal defect, TOF, double-outlet right ventricle (DORV)
Trisomy 21, Down syndrome40-50Ventricular septal defect, atrioventricular canal (AVC)
Del 22q11, DiGeorge syndrome (single gene etiology, autosomal dominant)50Truncus arteriosus, TOF, ventricular septal defect
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.